Lilly and Entos enter into research and collaboration agreement to support the development of innovative therapies in multiple neurologic indications
Torys acted as counsel to Entos Pharmaceuticals with a team that included Cheryl Reicin, Adam Falconi and Shmuel Giblon (corporate/life sciences).
On January 6, 2022, Eli Lilly and Company (“Lilly”) and Entos Pharmaceuticals, Inc. (“Entos”) announced that Lilly acquired exclusive rights to Entos’ Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic acid products targeting the central and peripheral nervous system.
Under the terms of the research and collaboration agreement, Lilly and Entos agreed to multiple programs focused on the development of proteo-lipid vehicles (PLV) for delivery of therapeutic cargo supplied by Lilly to targets in the central and peripheral nervous systems. Entos will be responsible for the generation, development and optimization of PLVs using its proprietary Fusogenix platform technology. Lilly will be responsible for selecting PLVs for clinical development and commercialization.
Entos will receive an initial payment of US$50 million, which includes an equity investment by Lilly in Entos. For each of the programs under the collaboration, Entos is also eligible to receive up to US$400 million in potential developmental and commercial milestone payments, as well as royalties upon the successful development and commercialization of products.
Further information can be found on PR Newswire’s website.
Entos is a clinical-stage biotechnology company that develops next generation nucleic acid-based therapies using its proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix is formulated with FAST proteins to deliver mRNA or DNA directly into the cytosol of target cells for translation into protective and therapeutic vaccines and medicines.
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world.